Lilly expands Abbisko Collaboration to $1.9B multi-target discovery deal, upgrading the Shanghai biotech from single-program partner to platform-wide discovery...

Abbisko Therapeutics expands its Lilly R&D collaboration, revealing how mid-stage oncology biotechs are trading equity upside for pipeline survival...

Nuvectis licenses NXP100 and NXP200 from Haisco for ex-China rights to two late-stage compounds targeting rare disease and oncology...

MacroGenics receives $24.5M from Sanofi following FDA accelerated approval of TZIELD Stage 3 Type 1 Diabetes, with $305M in...

Eli Lilly's Centessa Acquisition approved by UK High Court for $7.8B, securing orexin receptor agonist programs targeting sleep and...

Lilly's $7.8B Centessa acquisition, approved by UK High Court on June 22, reveals Big Pharma's new M&A logic: own...

Insilico Medicine and SK Biopharmaceuticals partner on neuroimmune drug discovery with a deal valued above $2.5 billion, targeting neuroinflammatory...

Teva filed an NDA for ecopipam, a first-in-class pediatric Tourette therapy, but orphan drug status and $15B in debt...

Eli Lilly partners with BioArctic on blood-brain barrier drug delivery platform in $30M upfront deal with $770M in potential...

SK pharmteco partners with Orphan Therapeutics Accelerator to advance rare disease programs through manufacturing support and preferential pricing.